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Purpose: To describe the development of a web-based high-quality data collection tool
to track the outcomes of treatment of macular disease in routine practice.
Methods: Testing of a larger data collection tool established which ﬁelds a clinician
would reliably ﬁll out. The program, which was developed using freely available software,
consists of modules interacting with a core system. The module for neovascular age-
related macular degeneration is described here.
Results: Data for initial visits can be entered within 30 seconds, 15 seconds for follow-up
visits. Fifteen centers from Australia, New Zealand, and Switzerland are currently
contributing data. Finalized data from 2,052 eyes of 1,693 participants dating from January
2006 were analyzed. Median (25th and 75th percentiles) visual acuity at the index visit was
55 (41, 68) logarithm of the minimum angle of resolution letters with the following lesion
types: minimally classic 17.2%, predominantly classic 24.6%, occult 52.0%, idiopathic
polypoidal choroidal vasculopathy 1.2%, and retinal angiomatous proliferation 3.2%.
Conclusion: This software tool will facilitate the collection of large amounts of data on the
routine use of treatments of neovascular age-related macular degeneration. This will allow us to
analyze important potentially modiﬁable variables, such as the effect of different treatment pat-
terns on visual outcomes, and to evaluate new treatments as they are introduced into practice.
RETINA 0:1–8, 2013
Unprecedented advances in the treatment of maculardiseases over the last decade have prevented
vision loss and blindness in many people. The discov-
ery that vascular endothelial growth factor is a major
driver of angiogenesis and vascular leak in the eye
provided the rationale for Phase 3 clinical trials that
demonstrated the efﬁcacy of the vascular endothelial
growth factor inhibitors. These studies examined rani-
bizumab (MARINA, ANCHOR),1,2 bevacizumab
(CATT),3,4 and aﬂibercept (VIEW 1 and 2)5 for neo-
vascular age-related macular degeneration (AMD).
Diabetic macular edema and retinal vein occlusion
are additional indications for vascular endothelial
growth factor inhibitors.6–9 Intravitreal steroid therapy
may also have a role in the treatment of macular
edema,10 particularly as agents formulated for the
eye become available (FAME study11).
Clinical trials determine whether new treatments work
in highly controlled conditions for a highly selected group
of patients that may not be representative of the general
patient population with the disease. The high experimen-
tal, or internal, validity of a clinical trial comes at a cost of
generalizability, or external validity, of its results. An
important question, therefore, is whether the promising
results of pivotal clinical trials translate to successful
patient outcomes in the general patient population under
real-life conditions. These questions are best answered by
population-based postmarketing observational studies.
Postmarketing surveillance refers to the ongoing
evaluation of a drug after its regulatory approval.
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Growing concerns about the safety of new medicines,
and increasing awareness of the potential beneﬁts of
using large-scale population-based data to monitor
product safety and effectiveness, have placed new
emphasis on the late-phase research agenda. Evidence
from such research has led to subsequent withdrawal
of drugs that had initially seemed promising in Phase 3
studies, such as cerivistatin (Lipobay, Bayer A.G.)12 or
rosiglitazone (Avandia, GlaxoSmithKline).13 By moni-
toring the general patient population undergoing varied
and individualized treatment regimens, postmarketing
observational studies complement earlier clinical trials.
They may determine small but signiﬁcant treatment
effects in routine clinical practice by tracking patients
for longer and collecting a different broader set of end
points, including safety, patient preference, quality of
life, and long-term effectiveness.
The Fight Retinal Blindness! (FRB!) Project has
designed an efﬁcient web-based data collection tool
speciﬁcally to track the outcomes of treatment of
macular disease in routine clinical practice. It is
anticipated that this “registry” will allow us to conﬁrm
whether outcomes of treatment in routine practice of the
new drugs for macular disease are consistent with the
promising results observed in the pivotal clinical trials.
We will compare different dosing regimens for their
ocular safety, long-term effectiveness, and patient
acceptance. We will also compare the outcomes
achieved by each individual drug in various clinical
settings. The system will allow individual physicians
to review their own data and compare their own results
against national benchmarks. In this study, we describe
the principles of design and development of this tool.
Methods
Structure of the Fight Retinal Blindness! Project
The FRB! Project consists of a Steering Committee,
an Executive Committee, a Publishing Committee, and
User groups. The Steering Committee, which is
elected at an annual meeting of Users in each country,
oversees the general development of the project, data
analysis, and publication, and coordination of the
different interests and requests from the User groups.
The Publishing Committee monitors publications and
adherence to the participation and publishing guide-
lines. The User groups are responsible for the
development of new modules or the modiﬁcation of
existing modules. For the purposes of this study,
“Users” are those entering data with the software,
whereas “Participants” are those whose outcomes are
tracked.
Software and System Design
Because the high prevalence of neovascular AMD
has rendered many retinal practices very busy, it was
believed critically important to reduce the load of
data capture by clinicians. Therefore, the choice of
data ﬁelds was guided by parsimony, validity, and
focus on achieving the registry’s purpose to track and
evaluate current and emerging treatments of macular
disease in routine practice after they have been
approved.14 Trialing a system with a large range of
data ﬁelds in one nonacademic and three academic
retinal practices revealed the minimum data ﬁelds
that practitioners would consistently complete.
Demographic data along with logarithm of the min-
imum angle of resolution (logMAR) visual acuity
and intraocular pressure may be entered by clinical
assistants. All other ﬁelds must be entered by the
treating physician.
Quality assurance (QA) measures were included to
ensure that only veriﬁed and high-quality data are
entered into the system. Data can be “Saved” if not
all the mandatory data are available or entered.
When all mandatory ﬁelds have been ﬁlled, the User
can “Finalize” the visit, starting a built-in validation
process that checks whether all mandatory ﬁelds
have been completed and that values are within
predetermined ranges, for example, visual acuity
must be between 0 and 100 letters. Only when data
are ﬁnalized, they are available for subsequent anal-
ysis and reporting. The system has been designed
in such a way that it will not allow a visit to be
ﬁnalized unless all the ﬁelds have been ﬁlled and
all numerical data fall within prespeciﬁed ranges.
From the *Save Sight Institute, Sydney Medical School, Univer-
sity of Sydney, Sydney, Australia; †Information and Communica-
tions Technology, University of Sydney, Sydney, Australia;
‡Marsden Eye Specialists, Parramatta, New South Wales, Australia;
§Lions Eye Institute, Center for Ophthalmology and Vision Science
and ¶Department of Population Health, University of Western Aus-
tralia, Perth, Australia; **Retina Associates, Chatswood, Sydney,
Australia; ††Department of Ophthalmology, Centre for Eye
Research Australia, University of Melbourne, Royal Victorian Eye
and Ear Hospital, Melbourne, Australia; ‡‡Department of Ophthal-
mology, Canberra Hospital, Canberra, Australia; §§Sydney School
of Public Health, University of Sydney, Sydney, Australia; and
¶¶Department of Ophthalmology, University Hospital Zurich, Zur-
ich, Switzerland.
Supported by a grant from the Eye Foundation (2007–2009) and
a grant from the National Health and Medical Research Council,
Australia (NHRMC 2010-1012).
M. C. Gillies is a Sydney Medical Foundation Fellow, M. C.
Gillies and R. Guymer are supported by the National Health and
Medical Research Council practitioner fellowships. D. Barthelmes
was supported by the Walter and Gertrud Siegenthaler Foundation
Zurich, Switzerland, and the Swiss National Foundation.
Reprint requests: Mark C. Gillies, Save Sight Institute, South
Block, 8 Macquarie Street, Sydney NSW 2000, Australia; e-mail:
mark.gillies@sydney.edu.au
2 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES  2013  VOLUME 0  NUMBER 0
Copyrightª by Ophthalmic Communications Society, Inc. Unauthorized reproduction of this article is prohibited.
The software used in the FRB! Project consists of
modules interacting with a core system. The core
system provides a range of basic functions, which are
used by each module for patient data management.
Each module provides the user with the functionality
to capture data for a speciﬁc purpose, in the ﬁrst in-
stance to collect data from patients receiving treatment
of neovascular AMD. The core system is modiﬁed and
changed only under very speciﬁc circumstances,
which have been approved by the Steering Committee.
Each user and user group, however, may create or
change modules which they can share with other users
should they be interested. Each registered FRB! Pro-
ject user can use the full scope of the software or select
only modules that ﬁt their needs.
The FRB! software is a web-based application,
which was developed using freely available software
such as Apache, MySQL, PHP, and RubyonRails.
This approach allows the application to be run on
different server operating systems. Any device with
Internet access and a recent browser can be used to
interact with the application.
There are two ways of entering data into the FRB!
system: via a web interface or via a third-party software
interface. If the User has no electronic patient manage-
ment system, the independent web-based application,
which can be accessed from a wide range of devices
and operating systems (e.g., Windows-PC, Macintosh,
tablet computer, mobile phone), can be used with
a regular browser (e.g., Safari, Internet Explorer, Fire-
fox, Opera). Additional software on the user’s terminal
is not required. If the user has an electronic patient
management system, this can be modiﬁed so that data
can be automatically transmitted electronically to the
project database, thus simplifying and expediting the
process for the user through single-point data entry.
Participant-reported outcomes are collected using
instruments such as the Impact of Vision Impairment
questionnaire.15 Responses are collected using a spe-
cially adapted application for tablet computers catering
for the special needs of the visually impaired, enabling
participants to choose color schemes and font sizes.
Data acquired using a tablet are transmitted directly
to the FRB! database for further analysis. The collec-
tion of PROs will facilitate studies to determine
whether improvements in visual acuity measured on
a chart are associated with improvement in visual
function and participant well-being.
Data Anonymity and Security
The FRB! Project software is designed to provide
maximum data security and anonymity. Users can
enter patient data into the respective module of the
FRB! software in an anonymized way. The system
then generates a unique identiﬁer (string of numbers
and letters) speciﬁc to each participant. This allows for
complete tracking of outcomes, even if the participant
is treated for different conditions by different doctors
at different locations. As well as the unique identiﬁer,
demographic data, such as the date of birth, gender,
initials, and ethnicity, are also stored. No other
personal information is recorded. All data transmis-
sions between the user and the server are encrypted
using 128-bit encryption (Secure Sockets Layer). The
data are stored and backed up on secure servers at The
University of Sydney’s Information and Communica-
tion Technology Department.
Anonymity of users is also closely guarded. Indi-
vidual Users can only see their own data and summary
descriptive data from their own country with which
they may compare their own outcomes. Users can
withdraw their data from the database at any time,
without providing a reason.
Ethical Considerations
Activities conducted by a health care provider,
which aim to monitor, evaluate or improve the quality
of care provided, are QA studies. The Australian
Health Ethics Committee considers that QA activities
are an essential and integral part of health care delivery
that should be encouraged and facilitated.16 Quality
assurance includes quality improvement activities such
as medical, clinical, and record audit and observational
studies, to which the ethical principles of research
apply. Clinical registries are established and operated
with the aim of improving patient care and outcomes
through greater understanding of events, treatments,
and outcomes,17 thus meeting the deﬁnition of a QA
activity.
A unique computer-generated string is assigned to
a patient automatically when their details are ﬁrst
entered into the system. This string makes the patient
unique in the database; it is not visible to the User. It is
linked to the User(s) own practice identiﬁers for each
patient. When the User subsequently enters the follow-
up data, the practice identiﬁer for that User can be
selected to create a follow-up visit. As an additional
measure to ensure that the right data are being entered
for the right patient, initials and date of birth are
shown.
Data registries must satisfy relevant regulations and
the requirements of the appropriate institutional
Human Research Ethics Committee (HREC), which
may vary from place to place. “Opt in” informed
patient consent, which greatly increases the onus of
work on the treatment provider and which can result
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in recruitment rates as low as one in six,18 may not be
necessary if all patients attending a practice consent to
the use of their anonymized data for clinical audit and
research purposes. Since the information collected in
the FRB! system is usually routinely collected by the
treating doctor and since the activity meets the require-
ments for a QA activity and does not breach individual
patient conﬁdentiality, HREC approval was sought in
Australia to conduct the Project as a QA or quality
improvement activity.
Each participating core center obtained approval
from their respective HREC to conduct the Project as
a QA activity. Overarching ethical approval was also
obtained from the Royal Australian and New Zealand
College of Ophthalmologists’ HREC to streamline the
process for participating private practices and to
ensure, from a central governance perspective, that
all users were aware and informed of their ethical
responsibilities. Documentation of HREC approval
from each center is copied to the central governing
ofﬁce to ensure currency of approval is maintained.
Data Export
Since the FRB! Project software is designed to be
a research tool, data export and analysis features are
very important. Individual Users can download their
own data at any time as a text ﬁle in comma separated
variable format. The software also offers statistical
tools for simple analyses. Users can export their own
data and analyze it as they see ﬁt for more sophisti-
cated analyses.
Statistical Methods
We calculated descriptive statistics for participants
at the Index visit, deﬁned as the ﬁrst visit at which an
intervention was commenced. For any cases where
a single patient contributed two eyes, only one was
randomly chosen for analysis to remove the possibility
of within-patient correlation biasing the results. For
continuous variables, we calculated the mean or
median and 25th and 75th percentiles. We summarized
categorical variables as percentages; participants with
missing data were not included in the denominator. All
analyses were performed with R version 2.15.0.19
Results
Data Fields for the Neovascular Age-Related
Macular Degeneration Module
The data captured by the FRB! application were
kept to a minimum to deliver an efﬁcient data
collecting tool. As a result of our experience with
the ﬁrst version, which had a large number of ﬁelds for
characteristics such as disease activity, a reﬁned set of
data elements were chosen such that an Index visit
could be entered in ,30 seconds and a follow-up visit
in ,15 seconds. Version 5 of the neovascular AMD
module has been operational since May 2010. The data
ﬁelds for the Index visit for this module are shown
in Table 1. Table 2 shows the ﬁelds for a follow-up
visit.
Table 1. Data Fields for a Baseline Visit
Field Subﬁeld
Date of visit
Treatment audit
Visual acuity in logMAR
Intraocular pressure
(not mandatory)
Ocular conditions Early AMD
Dry AMD
Neovascular AMD
Axial myopia
Vitreomacular
traction/PMF
Posterior uveitis
Diabetic retinopathy
Glaucoma
Clinically signiﬁcant
cataract
Pseudophakia
Amblyopia
Pre-treatments Laser
PDT
TTT
Triamcinolone
Anti-VEGF Lucentis
Anti-VEGF Avastin
Anti-VEGF Eylea
Other
Angiography lesion criteria Occult
Minimally classic
Predominantly classic
RAP
IPCV
Disciform scar
Juxtapapillary
Greatest linear dimension
CNV activity Active
Inactive
Unsure
Treatment type No treatment
Anti-VEGF Lucentis
Anti-VEGF Avastin
Anti-VEGF Eylea
Triamcinolone
TTT
Laser
PDT
CNV, choroidal neovascularization; PDT, photodynamic ther-
apy; VEGF, vascular endothelial growth factor; PMF, premacular
ﬁbrosis; TTT, transpupillary thermotherapy; IPCV, idiopathic
choroidal vasculopathy; RAP, retinal angiomatous proliferation.
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Graphical Displays
The software displays graphically visual acuity and
respective treatments given over time (Figure 1).
Mouse-over functionality reveals additional details
such as the change in number of letters read at the
selected visit compared with the previous visit and to
the Index visit. An enlarged version of the graph pro-
vides further functionality such as displaying the infor-
mation for each eye separately, zooming in and out, or
changing the time scale. Another feature is the ability
to compare the individual participant’s visual response
to treatment with the results of the sham-treated groups
from the MARINA1 Study and the Macular Photoco-
agulation Study20 (Figure 2).
Uptake and Usage
Use of the FRB! software has steadily gained
momentum. Currently, 13 centers in Australia, 1 in
New Zealand, and 1 in Europe are contributing data.
Logarithm of the minimum angle of resolution visual
acuity was measured by eight users, who tended to be
from the larger academic centers, whereas ﬁve Users,
more from smaller private practices, measured Snellen
visual acuity which they transferred to logMAR letters
using a chart that is available on the data entry screen.
Royal Australian and New Zealand College of Oph-
thalmologists has accredited the FRB! software appli-
cation as a self-audit tool that can be used to gain
points under the clinical audit section of their con-
tinuing professional development program.
Table 2. Data Fields for Follow-up Visits
Field Subﬁeld
Date of visit
Treatment audit
Visual acuity in logMAR
Intraocular pressure
(not manadory)
CNV activity Active
Inactive
Unsure
Treatment type No treatment
Anti-VEGF Lucentis
Anti-VEGF Avastin
Anti-VEGF Eylea
Triamcinolone
TTT
Laser
PDT
Adverse events Patient reported postinjection
pain
RPE tear
Hemorrhage-reduced BCVA
by .15 letters
Infectious endophthalmitis
Noninfectious endophthalmitis
Retinal detachment
Cataract extraction/other
intraocular surgery
Discontinue treatment? Treatment successful
Further treatment futile
Patient goes to another doctor
Patient declines
Medically contraindicated
Deceased
BCVA, best-corrected visual acuity; CNV, choroidal neovas-
cularization; PDT, photodynamic therapy; RPE, retinal pigment
epithelium; VEGF, vascular endothelial growth factor; TTT, trans-
pupillary thermotherapy.
C
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Fig. 1. Visual acuity of a single patient since starting treatment in June
2006. Intravitreal treatment with bevacizumab (green bars) and ranibi-
zumab (purple) is indicated on top of the graph. Visual acuity in the
right eye declined initially then improved steadily after changing from
bevacizumab to ranibizumab in October 2008 and increasing the
injection frequency. Mouse-over function shows that at the last visit,
visual acuity was 75 logMAR letters, the difference to the previous
visits was −5 letters, and the difference to the Index visual acuity was
also −5 letters.
C
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R
Fig. 2. Visual acuity of the same patient shown in Figure 1 plotted as
change in logMAR letters compared with the Index visit for each eye.
The green line represents data obtained from the sham-treated groups
from the MARINA and Macular Photocoagulation Study.
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Participant Characteristics
Finalized data from 2,052 eyes of 1,693 participants
were available for this analysis. Thirteen Users
contributed data, median 104 eyes (range, 26–304).
Although the proportion of eligible patients that the
User tracked with the system was not audited, it was
speciﬁed in the Users’ agreement that data should be
entered on at least 85% of patients in the User’s prac-
tice that are eligible to have their data included. This is
also a condition for Users applying for Continuing
Professional Development points, which are a require-
ment for Medical Board registration in Australia.
The ﬁrst recorded anti–vascular endothelial growth
factor treatment was administered in January 2006. A
total of 34,168 visits have been recorded with a total of
25,467 treatments. Of all participants to date, 60.9%
were women; the mean (25th and 75th percentiles) age
at the index visit was 79.7 (75, 85) years for women and
78.4 (74, 85) years for men. Median (25th and 75th
percentiles) visual acuity at the index visit was 55
(41, 68) logMAR letters. A histogram of visual acuity
at the index visit is presented in Figure 3. The lesion
types were distributed as follows: minimally classic
17.2%, predominantly classic 24.6%, occult 52.0%, idi-
opathic polypoidal choroidal vasculopathy 1.2%, and
retinal angiomatous proliferation 3.2% (others 1.8%).
Discussion
In response to the unmet need for postmarketing
observational studies of the emerging treatments of
macular disease, we have created an efﬁcient web-
based system to collect high-quality outcome data
from routine clinical practice. The system has been
designed to extract the maximum amount of informa-
tion from a minimal data set to produce beneﬁts for all
stakeholders. Although postmarketing observational
studies produced data that are not as clean as those
from randomized clinical trials, “registries can be more
evidence-based than the traditional framework of ran-
domized controlled trials for care improvement.”21
An important principle in registry design is to reduce
the load of data entry.14 Reduced burden facilitates data
entry at the time of the consultation and improves data
quality by limiting complexity. The collection of just
the four variables, treatment, date, logMAR visual acu-
ity, and grading of activity to active or inactive allows
many important questions to be asked in people being
treated for neovascular AMD. For example, different
treatment patterns, such as monthly, pro re nata, and
“inject and extend,” can be identiﬁed and their out-
comes are compared. Eyes may be matched to the Index
visit of participants in pivotal Phase 3 clinical trials to
establish whether their results are reproducible in the
general population.
Observational registry-based studies such as this one
have advantages for stakeholders at every level. Physi-
cians get a real-world picture of current treatment
patterns and outcomes. They can compare their results
with those of other clinicians22. Physician organizations
can assess the degree to which diseases are being
managed according to evidence-based guidelines. Gov-
ernment and industry stakeholders can see how interven-
tions are being used and what their effectiveness is in the
general patient population. Pharmaceutical companies
may fulﬁll some of their obligations for postmarketing
surveillance. Data can also be used to develop new
hypotheses for interventions in speciﬁc patient popula-
tions. Graphical display of an individual’s visual acuity
response to treatment may improve participant under-
standing of their disease and treatment compliance, as
well as facilitating patient ﬂow through the practice.
Some early reports of postmarketing observational
studies for neovascular AMD have recently appeared.
The Swedish Lucentis Quality Registry, a 12-month,
open-label observational study of ranibizumab for wet
AMD, reported visual acuity results after a mean of
4.7 injections over 12 months in 370 patients. The
authors speculated that treatment might not have been
applied sufﬁciently aggressively.23 The GermanWAVE
study of 3,633 people receiving treatment of wet AMD
reported that many fewer people were accessing treat-
ment with intravitreal therapy than expected.24 The
Swedish Macular Register (http://www.eyenetsweden.
se/page/28/the-macula-register.aspx, accessed August
21, 2012) does not appear to have released any
reports yet. The LUMINOUS study is an ambitious
project sponsored by Novartis to track the outcomesFig. 3. Histogram of visual acuity at the index visit.
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in 30,000 patients worldwide receiving intravitreal
ranibizumab (Clinicaltrials.gov identiﬁer NCT01318941).
Far larger observational studies that have been
established in ophthalmology to monitor the outcomes
of anterior segment surgery demonstrate the potential
beneﬁts of this approach. Registries commonly track
safety, but they may also track long-term efﬁcacy of
interventions. The Swedish National Cataract register
reported the outcomes of over 1 million cataract
operations performed between 1992 and 2009.25 They
found that the risk of complications declined while
outcomes improved over this period. These data serve
as benchmarks against which further improvements
may be measured. The European Registry of Quality
Outcomes for Cataract and Refractive Surgery ana-
lyzed the outcomes of 820,000 cases performed from
2009 to 2011 to produce best practice guidelines.26
The Australian Corneal Graft Registry, established in
1986, tracked around 15,000 penetrating corneal grafts
to ﬁnd that the success rate fell from 87% at 1 year to
46% 15 years after surgery.27
We have taken steps to minimize a number of
potential biases that may affect observational studies.14
“Information bias,” in which Users may misreport the
outcome of an intervention if they have a vested interest
in doing so, is avoided by making User data available
only to the individual User. This also reduces “selection
bias,” by which Users enroll only patients who have
a low risk of complications. “Channelling bias” may
occur when drugs with similar therapeutic indications
are prescribed to groups of patients with prognostic
differences, such as those who have failed ﬁrst-line
treatment. Our system therefore includes all possible
interventions for the condition being audited and col-
lects data on previous treatments. Loss to follow-up can
be a concern if it is nonrandom. To reduce the incidence
of this, we have established a referral function within
the system so that participants’ data can be transferred
seamlessly from one service provider to another as long
as they are both participating in the project.
We have described here the principles of develop-
ment of a software tool that forms the basis of a registry
for the outcomes of treatment of macular disease. This
will allow us to analyze a number of important poten-
tially modiﬁable variables, such as the effect of different
treatment patterns on visual outcomes. New treatments
will be evaluated as they are introduced into practice.
Participation in the project, which is expected to be
organized along national lines, remains open and free to
individual users.
Key words: patient outcome registry, age-related
macular degeneration, postmarketing observational
study, vascular endothelial growth factor inhibitors.
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Appendix. Full Study Group Membership for the
Fight Retinal Blindness! Project
Eye Surgeons Miranda, Miranda, New South Wales,
Australia (Dr. A. Hunt); Eye Associates, Sydney, New
South Wales, Australia (Dr. M. Gillies and Dr. A. Hunt);
Retina Associates, Chatswood, New South Wales,
Australia (Dr. A. H. Hunyor, Dr. S. Fraser-Bell, and
Dr. C. Younan); Marsden Eye Specialists, Parramatta,
New South Wales, Australia (Dr. J. Arnold and
Dr. D. Chan); Gladesville Eye Specialists, Gladesville,
New South Wales, Australia (Dr. S. Young); Hornsby
Eye Specialists, Hornsby, New South Wales, Australia
(Dr. S. Lal); Northern Rivers Eye Surgeons, Lismore,
New South Wales, Australia (Dr. G. Clark and
Dr. N. Aboud); Eyemedics, Adelaide, South Australia,
Australia (Dr. S. Lake, Dr. R. Phillips, and Dr. M. Perks);
Canberra Hospital, Garran, ACT, Australia (Dr. R. Essex);
Cairns Eye and Laser Clinic, Cairns, QLD, Australia
(Dr. A. Field); Queensland Eye Institute, South
Brisbane, QLD, Australia (Dr. T. Kwan); Lions
Eye Institute, Nedlands, Western Australia, Australia
(Prof. I. McAllister, Ass Prof. F. Chen, Dr. T. Isaacs,
and Prof. I. Constable); Centre for Eye Research
Australia, East Melbourne, Victoria, Australia (Prof.
R. Guymer, Dr. R. Troutbeck, and Dr. D. Louis);
Cheltenham Eye Centre, Cheltenham; Bayside Eye
Specialists, Brighton East; Southern Eye Centre,
Frankston, Victoria, Australia (Dr. D. Louis); Victoria
Parade Eye Consultants, Fitzroy, Victoria, Australia
(Prof. R. Guymer, Dr. L. Lim, and Dr. A. Harper);
Doncaster Eye Centre, Doncaster, Victoria, Australia
(Dr. S. Wickremansinghe and Dr. L. P. Chow);
Caulﬁeld Eye Clinic, Caulﬁeld, Victoria, Australia
(Dr. R. Troutbeck and Dr. S. Wickremasinghe); Special-
ists Eye Group, Glen Waverly, Victoria, Australia
(Dr. S. Wickremasinghe and Dr. L. P. Chow); Eye
Institute, Auckland, New Zealand (Dr. P. Hadden);
ADHB, Auckland, New Zealand (Dr. D. Squirrell);
Milford Eye Clinic, Auckland, New Zealand
(Dr. D. Squirrell); University Hospital Zurich,
University of Zurich, Zurich, Switzerland
(Dr. D. Barthelmes); Retina Specialist Auckland,
New Zealand (Dr. D. Sharp, Dr. R. Barnes, and
Dr. P. Hadden).
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